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ABSTRACT
There is a need for inexpensive and reliable means to determine the modulation of cutaneous inflammation. The method 
outlined in this article draws together a number of scientific techniques and makes use of generally unwanted biological 
tissues as a means of determining skin inflammation ex vivo, and focuses on probing aspects of the arachidonic acid 
inflammation pathway. Freshly excised skin contains elevated levels of short-lived inducible cyclooxygenase-2 (COX-2) 
and, under viable conditions, COX-2 and its eicosanoid products will continue to be produced until tissue necrosis, 
providing a window of time in which relative levels can be probed to determine exacerbation due to an upregulating 
factor or downregulation due the presence of an agent exerting anti-inflammatory activity. Ex vivo porcine skin, mounted 
in Franz diffusion cells, is dosed topically with the xenobiotic challenge and then techniques such as Western blotting 
and immunohistochemistry can then be used to probe relative COX-2 levels on a semi-quantitative or qualitative level. 
Enzyme-linked immunosorbent assay or LCMS can be used to determine relative prostaglandin E-2 (PGE-2) levels. 
Thus far, the technique has been used to examine the effects of topically applied anti-inflammatories (betamethasone, 
ibuprofen, ketoprofen and methotrexate), natural products (fish oil, Devil’s claw extract and pomegranate rind extract) 
and drug delivery vehicle (polyNIPAM nanogels). Topically applied xenobiotics that modulate factors such as COX-2 
and PGE-2 must penetrate the intact skin, and this provides direct evidence of overcoming the "barrier function" of the 
stratum corneum in order to target the viable epidermis in sufficient levels to be able to elicit such effects. This system 
has particular potential as a pre-clinical screening tool for those working on the development of topical delivery systems, 
and has the additional advantage of being in line with 3 Rs philosophy.
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INTRODUCTION
Skin and inflammation
Covering most of the body, the epidermis comprises a structured 
epithelium with five histologically distinct regions. With a turnaround 
time of approximately 4 weeks, keratinocytes of the epidermis basal 
layer undergo progressive transformations culminating in the formation 
of the outermost layer, the stratum corneum, before being shed from 
the surface via desquamation. The stratum corneum is a dense, non-vi-
able tissue some 15 microns in thickness, in which the cells are fully 
differentiated and known as corneocytes. The purpose of this layer is 
to provide a “barrier function” by presenting a largely impenetrable, 
rate-limiting obstacle to the ingress of xenobiotics, ultraviolet (UV) 
radiation and microbes, whilst also limiting the egress of water and 
electrolytes [1]. The viable epidermis, in particular the basal layer, is 
highly metabolically active and expresses many phase I non-CYP and 
phase II enzymes [2] which respond to a range of stimuli such as trauma 
and xenobiotic or UV radiation ingress, and often results in activation 
of the arachidonic acid (AA) inflammation pathway, described later. 
The viable epidermis is also host to dendritic Langerhans cells that 
reside in the suprabasal layers of the epidermis in close contact with 
keratinocytes and help to prevent infections.
Inflammatory skin diseases are the most common problem encoun-
tered by dermatologists, ranging from superficial rashes to chronic 
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conditions such as dermatitis (eczema), contact dermatitis, rosacea and 
psoriasis. Acute inflammation can result from exposure to UV irradiation, 
ionizing radiation, allergens, or to contact with chemical irritants, and is 
typically resolved within 1 to 2 weeks with little accompanying tissue 
destruction. Chronic inflammation results from prolonged immune cell 
mediated inflammatory response within the skin, and are long lasting 
with potential to cause serious tissue destruction, and are products of 
interplay between complex regulatory networks [3]. In the dermis, 
dendritic myeloid cells are involved in the pathogenesis of immune 
system related inflammatory disorders such as psoriasis by producing 
pro-inflammatory cytokines such as interleukins [4].
Mechanisms of skin inflammation
The process of skin inflammation is complex and is still not com-
pletely understood, and it can be triggered by a stimulus, a chemical 
irritant (e.g., xenobiotic) or allergens. Skin inflammation can also be 
associated with autoimmune conditions and can spread to skin from the 
main inflammation focus such as a joint affected by rheumatoid arthritis, 
or in the reverse direction as is the case with psoriatic arthritic. A further 
important stimulus in skin inflammation is UV radiation and cultured 
human keratinocytes irradiated with UVB showed a 6-fold increase in 
cyclooxygenase-2 (COX-2) that was evident at 6 h and peaked 24 h 
after irradiation [5]. Each of these causes the cells in the skin produce 
a variety of cytokines and chemokines that bind to specific receptors 
on target cells and stimulate the production of additional inflammatory 
signalling factors. Some of these cause vasodilation, resulting in famil-
iar skin erythema and activation of nerve cells, causing pain. The two 
major inflammatory mediators involved in skin disorders are tumor 
necrosis factor (TNF)-α and prostaglandin E2 (PGE-2). While TNF-α 
plays a key role in immune system-based inflammation processes such 
as psoriasis, PGE-2 is a major factor in all types of skin inflammation, 
and many other tissues [6].
The cyclooxygenases (also known as prostaglandin-endoperoxide 
synthases) is a family of three known enzymes. COX-1 is expressed 
constitutively, i.e., it is produced by a cell under all types of physiological 
condition, predominating in the kidney, stomach and platelets. COX-3 
is a relatively recent discovery and is not believed to be of interest in 
humans. The main analytical target in the current article is COX-2 which 
is an inducible enzyme that is the product of an “immediate-early” 
gene and is generally expressed only in cells where prostaglandins are 
upregulated, e.g., during trauma or inflammation—it is unexpressed 
under normal conditions, but elevated levels are found during episodes 
of trauma, irritancy and inflammation [7,8]. In the skin, COX-2 is ex-
pressed predominantly in suprabasal keratinocytes [5].
Regardless of subtype, the primary function of COX is to catalyze the 
production of eicosanoids from polyunsaturated fatty acid AA, which 
is stored in the phospholipids of bodily cells and is liberated from cell 
membranes upon demand, when COX converts it to prostaglandin G2 
and prostaglandin H2. PGH2 is converted by prostaglandin E2 synthase 
into the potent inflammatory mediator PGE-2. COX-2 also converts AA 
to 15-hydroxyicosatetraenoic acids (15-HETE). Conversion of AA to 
is a two-step process [9]. Firstly, hydrogen is abstracted from C13 of 
AA, and two atoms of oxygen are added by the COX-2, giving PGG2. 
Secondly, PGG2 is reduced to PGH2 in the peroxidase active site. PGH2 
is subsequently converted to prostaglandins (PGD2, PGE2, PGF2α), 
prostacyclin (PGI2), or thromboxane A2 by tissue-specific isomerases.
Crucially, in relation to the methodology that is the focus of this 
article, COX-2 has a short lifespan of 1–2 min at Vmax and becomes 
permanently inactivated after converting several hundred AA molecules 
[10]. As inflammatory mediators such as COX-2 have such short half-
lives, constant stimulation is needed to maintain inflammation. In this 
way, any unnecessary inflammation is kept to a minimum. Conversely, 
once the injury is repaired, or other stimulus has been removed, the 
inflammatory cells begin to return to normal status. Similarly, levels 
of COX-2 production will diminish if an anti-inflammatory agent is 
present in sufficient quantity such that it can block the enzyme or 
interfere with another part of the AA inflammatory pathway upstream 
or downstream of COX, or the tissue loses viability. Over-expression 
of COX-2 and its product PGE-2 has been implicated in the aetiology 
of other disease states, such as restricted airflow in chronic obstructive 
pulmonary disease, COPD [11] and degenerative brain diseases [12]. The 
expression of COX-2 is known to be upregulated in many cancers, with 
high levels of PGE-2 implicated in breast [13] and skin cancer [5,14].
Drug therapy for skin inflammatory conditions
Therapeutic drugs to treat skin conditions can be administered either 
via the systemic circulation by injection or oral dose, or by local or 
topical delivery using a cream or gel formulation. The most common-
ly-used prescription drugs for treating skin inflammation arising from 
the cellular immune system include corticosteroids which are effective 
for eczema, including atopic dermatitis, allergic contact dermatitis, 
seborrheic dermatitis and psoriasis. However, first-line treatments tend 
to involve non-steroidal anti-inflammatory drugs (NSAIDs)—these 
possess analgesic, antipyretic and anti-inflammatory properties which 
inhibit prostaglandin production by blockade of cyclooxygenase active 
sites. Drugs aimed at treating skin inflammation (anti-inflammatories) 
are administered either systemically or topically—each with advantages 
and disadvantages. Oral systemic administration results in a very small 
amount of drug reaching the target inflamed skin, with the remainder 
interacting with other parts of the body unnecessarily—also, for pro-
fen-type NSAIDs, there are recognized risks of gastrointestinal upset 
and even heart failure [15]. The selective COX-2 inhibitors (Coxibs) 
have been associated with adverse effects [16]. Local administration, 
typically via cream or gel formulations, requires lower doses and in-
volves minimal systemic absorption, but the drug must overcome the 
skin barrier function (except where the skin is already compromised, 
e.g., psoriasis).
A large variety of products is available for treating skin inflamma-
tion, both on prescription and over the counter, including hydrocorti-
sone, betamethasone in addition to NSAID products such as Ibuleve 
(ibuprofen), Feldene (piroxicam) and Voltaren (diclofenac); the latter 
also indicated for relieving subcutaneous musculoskeletal pain. The 
delivery of anti-inflammatory drugs into and across remains a highly 
active research area, indicative of a continued clinical need for more 
efficacious products and methods by which to evaluate them. There are 
consequently many articles in the literature concerned with the dermal 
or transdermal delivery of anti-inflammatories [17], which are often 
used to test novel topical drug delivery systems, such as nanoparticles 
[18]. Typically these involve comparative drug transport by obtaining 
kinetic parameters, where data are often rationalized using Fickian 
laws or algorithms [19], or depth profiling whereby adhesive tape is 
used to sequentially strip skin layers which are then analyzed for drug 
content [20]. However, determining the mass transport across or mass 
localization within the skin alone does provide direct information 
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relating to biological activity. Topically applied compounds that are 
observed to modulate COX-2 expression, either anti-inflammatory 
or pro-inflammatory, must ipso facto penetrate the skin in sufficient 
levels and penetrate viable cells allowing sufficient interaction with 
the inflammation factors, such as inhibiting COX-2.
Overall, new products aimed at relieving (skin) inflammation hence 
pain management are still needed. On the other hand, it is equally 
important to determine the toxicological potential or risk of topically 
applied compounds that are capable of inducing skin inflammation 
(pro-inflammatories). There is thus a need for robust, accurate methods 
for determining modulation of skin inflammation by xenobiotics that 
have successfully penetrated the barrier function of the stratum corne-
um. Furthermore, in the modern era new methods would be expected 
not involve the use live animals, broadly in line with 3 Rs goals [21].
Current models of determining skin inflammation mod-
ulation
In vivo human trials are clearly the most reliable means of deter-
mining the effect of topically applied xenobiotics, however due to the 
enormous costs they are used only to evaluate final products. Live 
animal experimentation is consequently commonplace and numerous 
approaches have been used. In the TPA-induced mouse ear oedema 
technique the potent tumor promoter 12-O-tetradecanoylphorbol-13-ac-
etate (TPA), derived from croton oil, which oedema and swelling when 
applied to the ears of mice. TPA applied topically on mouse ear skin 
induces vascular permeability, increases formation of leukotrienes and 
prostaglandins, increases the influx of neutrophil and macrophages, 
and induces proinflammatory cytokines, including TNF-α, interleukin 
(IL)-1β and IL-6 [22,23]. The blockade of upstream kinase IκBα ki-
nase signaling by the natural phenolics tannic acid and protocatechuic 
acid, inhibited the enzyme level and the activity of COX-2 [24]. Ear 
punch biopsies are taken from the TPA treated mouse ears to measure 
weight changes [25,26]. Carrageenan-induced rat paw oedema model 
uses an irritant polysaccharide extracted from seaweed, which induces 
inflammation, vasodilatation and increases vascular permeability [27]. 
Anti-inflammatory activity of the topically applied xenobiotic is assessed 
by measuring their ability to reduce or prevent local inflammation caused 
by carrageenan injected into the paw of rats. Rat paw oedema can be 
quantified by a number of approaches [28].
As the major cytokine-releasing cells in the viable epidermis, the 
study of inflammation in keratinocytes has been detailed in numerous 
papers. In resting keratinocytes, immune mediators are at very low 
levels, however, under stimulatory conditions keratinocytes express 
cytokines, chemokines and accessory molecules, which transmit signals 
to cells of innate and adaptive immunity. Dysregulation and abnormal 
expression of inflammatory mediators in keratinocytes are implicated in 
the pathogenesis of chronic inflammatory skin diseases [29]. Cultured 
human keratinocytes were used to determine the effect UVB irradiation 
on COX-2 [5]. Keratinocytes have been widely used to model xenobi-
otic action in skin, for example the modulation of keratinocyte COX-2 
expression was used in determining the anti-inflammatory effects of 
novel drugs, such as dithranol derivatives [30]. HaCaT cell line is a 
spontaneously immortalized, human keratinocyte which is widely used 
for skin biology studies, including inflammation such as cytokines 
IL-6, IL-8, IL-10 [31]. However, HaCaT cells were shown to produce 
100-fold less PGE-2 than normal human epidermal keratinocytes, 
supporting the hypothesis that COX-2 activity was reduced as a result 
of immortalization [32]. Also, such a purely in vitro system is clearly 
incapable of responding in proportion to drug challenges arising from 
topically applied doses.
Much research has led to the development of tissue engineered re-
constructed skin. Commercially available systems generally comprise 
a reconstituted organotypic culture of human keratinocytes forming a 
multilayer differentiated epidermis on a collagen matrix. The European 
Union Reference Laboratory for Alternatives to Animal Testing (EC-
VAM) introduced validated test tests for acute irritation potential from 
exposure to acutely irritant substances contained in various products 
using EpiSkin, EpiDerm SIT, Modified Epiderm and SkinEthic models 
(ECVAM). Studies on the activity of pro-inflammatory cytokines such 
as interleukins have been reported [33-36]. However, we were unable to 
locate literature reports on the use of these materials for determination of 
modulation of the AA inflammation pathway, the key target of topically 
delivered NSAIDs. A proteomic profile of the xenobiotic metabolizing 
enzymes in native human skin was compared with data obtained from a 
number of in vitro models of human skin, with considerable variability 
being shown [32]. Although such materials could be used to study skin 
inflammation, these tissues lack a recognizable fully differentiated 
stratum corneum, complete with appendages, as is found in vivo, and 
are therefore unlikely to accurately reflect inflammation modulation 
as a function of skin penetration. Furthermore, skin appendages (pi-
losebaceous units and sweat pores) are recognized as important “shunt 
routes” in the delivery of drugs into and across the skin [1], and can 
influence the timescale over which xenobiotics penetrate the skin and 
modulate inflammation [37].
Porcine ear skin as a model for human skin
Porcine (pig) skin has been used extensively in recent years as a model 
for human skin in topical penetration and permeation experiments. The 
driving force for this is largely due to the ethical and regulatory hurdles 
involved with using excised human skin. Other factors include its general 
availability and the sizeable areas of tissue available—workers sometimes 
use mouse or rat skin, where the available area of tissue is limited, for 
example the area of the dorsal surface of a pig ears versus the dorsal 
side of a mouse. Porcine organs are generally very similar to human skin 
and this has led to considerable research into xenotransplantation. The 
validity of the porcine skin model is supported in numerous published 
articles where it has been favorably compared to human skin in terms 
of: xenobiotic permeability [38-40], architecture [41-43], biology [44] 
and immunology [45,46]. Of the regions of porcine skin, the dorsal side 
of the ear is considered to be most similar to human skin and up to 15 
Franz diffusion cells (FDCs) can be set up using skin from a single pig 
ear. However, variations in histology have been reported in porcine 
skin [47], a fact which must be borne in mind when interpreting data.
COX-2 and PGE-2 determination in ex vivo skin
Freshly excised porcine skin is metabolically active and contains 
elevated levels of the COX-2 due to the trauma of preparation and 
this is observed universally in our laboratory. If viable conditions are 
maintained COX-2 will continue to be produced until the inducing 
stimulus is removed or an anti-inflammatory agent is present. An ex 
vivo scenario can be described as one in which tissue is maintained in 
a state of viability once excised from the animal. The determination 
of relative COX-2 levels has been used in ex vivo tissue to determine 
anti-inflammatory, and in some cases pro-inflammatory, effects of a 
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range of topically applied compounds. In a typical experiment, described 
shortly, a skin explant is mounted in a Franz diffusion cell and COX-2 
modulation is then probed in the skin after an appropriate incubation 
period. The following is a typical experimental procedure.
MATERIALS
A convenient experimental set-up involves the FDC—a simple 
two-compartment device comprised of a donor compartment and recep-
tor compartment that allow the determination of xenobiotic transport 
from the donor phase (in contact with the stratum corneum) into the 
skin or through it skin to the receptor phase [48]. FDCs are available in 
different forms—those used in the author’s laboratories have a nominal 
diffusional area of 1 cm diameter (0.88 cm2) and receptor phase volume 
of 3 ml (Fig. 1).
Figure 1. All-glass Franz diffusion cell, comprised of an upper donor phase and lower receptor phase. The skin membrane is positioned stratum 
corneum uppermost, between the 2 flanges and clamped together; the receptor phase filled with Hanks buffer and the skin dosed with the test substance.
Freshly excised porcine ears must be collected as soon as possible 
after slaughter. To facilitate the longevity of skin viability, the tissue is 
immersed in iced Hanks buffer, during transportation to the laboratory; in 
the author’s laboratory this is typically achieved within 1 h. As the animal 
has already undergone humane slaughtering, no ethical considerations 
apply regarding further procedures. However, the animals arriving at 
the abattoir have not been reared under laboratory conditions. Hence, 
there is a great deal of variation in the quality and cleanliness of the 
ear tissue, and one should only use unscarred, relatively clean material. 
Further gentle cleansing under running water is usually sufficient. In 
terms of breed, the “large white” are the most common and it is easier 
to spot defects and indeed to visualize stained COX-2 relative to other 
breeds that may have high melanin content and therefore obscure 
visualization. Also, it is of immense importance to stress here that the 
ears must be removed from the pig prior to undergoing sanitation, often 
by steam cleaning—a process which strips away the entire epidermis, 
clearly rendering the tissue unsuitable for experimentation.
Hanks buffer balanced salt or DMEM. Molecular biology reagents for 
example kits for analyzing COX-2 and prostaglandin; reagents necessary 
to perform immunohistochemical (IHC) and Western blot analysis, as 
detailed later. In typical transdermal delivery experiments, the choice 
of receptor phase is normally dictated by the need to provide “sink” 
conditions for the permeant drug, otherwise artificially high levels of 
drug can accumulate in the skin tissue. However, in an ex vivo scenario 
the receptor phase must also fulfill a further critical function—one 
of maintaining skin viability. Hanks balanced salt solution has been 
proven to maintain skin viability and is typically used in our laboratory 
and by other workers [49]. For polar permeants, Hanks buffer alone is 
sufficient. However, Hanks buffer must be altered in order to provide 
a sink for lipophilic permeants. An “organic modifier” such as alcohol 
such as methanol and ethanol should be avoided for compromising 
tissue viability; some success was obtained using DMSO. However, 
the most effective modifier we have found is the quaternary ammonium 
surfactant cetrimide, which is miscible with Hanks buffer and at levels 
of 30% does not compromise skin viability [50,51].
PROCEDURE
Ex vivo skin preparation
Once in the laboratory, the ears are cleansed under running water, 
hairs trimmed and the skin (typically the dorsal side only for consisten-
cy) liberated from the underlying cartilage by blunt dissection using a 
scalpel, whilst being continually bathed in Hanks buffer. Some papers 
use epidermal membranes liberated from full thickness skin by heat 
separation—however, the process deactivates skin metabolism, and 
so such tissue is not appropriate for use in this protocol. Skin sheets 
may then be further cut into 2 cm2 sections, carefully excluding areas 
containing scars and defects, and then used immediately.
Topical delivery
The ex vivo skin sample is mounted stratum corneum-uppermost, 
between the lightly pre-greased flanges and clamped into position—the 
purpose of the grease is to prevent leakage of liquid donor and receptor 
solutions, and should be used very sparingly. A micro-stirrer bar is 
added to the receptor compartment to assist mixing after placing on 
a stirrer plate, filled with degassed receptor phase, and the sampling 
arm capped. The complete cells are placed on a multiple stirrer plate 
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in a thermostatically controlled water bath set at 37°C which generally 
provides a skin surface temperature of 32°C. After an equilibration 
period of typically 15 min, the donor phase is then dosed with the 
test xenobiotic—this can be in the form a solution or a formulation 
such as a cream, gel or even section of a transdermal patch. “Finite” 
doses are intended to simulate an in-use dosing regimen (e.g., a fixed, 
representative amount of formulation to be applied per area of skin, 
e.g., 20 mg/cm2) but, even after repeat-doses, this may not demonstrate 
that delivery to the viable epidermis has been achieved (i.e., < limit of 
detection of the assay). For maximal effect “infinite” doses, typically 
1 ml, may be applied which is in sufficiently high concentration to 
show demonstration and achievement 0-order transport kinetics. To 
determine transdermal delivery parameters such as steady state flux 
and lag time, samples are taken from the receptor phase and analyzed 
for penetrant [48]. However, receptor phases may also be collected 
and used to re-apply apply to ex vivo skin to indicate that the levels of 
permeated compounds are able to exert an anti-inflammatory effect in 
deeper tissues [37,52]. At predetermined times, that should reflect an 
in-use situation, the FDC is dismantled and the skin membranes recov-
ered. Excess formulation is carefully removed before the immediate 
commencement of biological analysis. At this stage, quantitative skin 
penetration data may be obtained using the tape stripping technique 
[20,37,48], whereby adhesive discs or tape is repeatedly applied to and 
removed from the area of drug application and the amount of drug then 
quantified; this is useful for determining the amount of drug localized 
at different stratigraphic/histological layers within the skin. Summating 
these amounts provides an estimation of drug reservoir (per unit area). 
Naturally, such work will involve different skin samples as tape stripping; 
for example, tape stripping is known to be a pro-inflammatory process, 
causing a transient increase in skin COX-2 mRNA [53]. Koppes et al. 
used in vivo tape stripping followed by the analysis of 38 inflammatory 
mediators to probe topical therapy of dermatitis [54].
We have used “reverse-tape stripping” to provide more direct quan-
titation of xenobiotics successfully reaching and localizing within the 
viable epidermis—the technique is as above, but uses isolated epider-
mis and application of the first tape strip to the basal layer rather than 
stratum corneum.
Preparation of skin lysates
The first step in the process is the preparation of skin lysates in 
order to release the protein content including COX-2 [53]—this must 
be carried out very promptly to minimize further metabolic change. To 
prepare the skin lysates, the diffusional area of application from the 
FDC is excised by blunt dissection using a scalpel, cut into small pieces 
and added to 1 ml radioimmunoprecipitation lysis buffer. Additional 
protease inhibitors are added immediately prior to maceration using a 
probe homogeniser 1 min. Crude lysates are incubated for 15 min on 
ice then pelleted by centrifugation at 1400 g for 2 × 15 min at 4°C, 
and the supernatant stored at −20°C. Inflammatory mediators can then 
be probed, and two main techniques have been used—these are well 
known techniques and so only a brief synopsis is given.
Western blotting analysis of COX-2
Western blotting (WB) is a well-established analytical tool for 
protein identification and quantitation, with methods that are well 
described in the literature [5,55,56]. The protocol used, including the 
major steps of protein estimation and denaturation, polyacrylamide gel 
electrophoresis, transfer, blocking, detection/probing using primary 
antibody and secondary antibody/reporter conjugate can be found in 
Abdelouahab Ouitas and Heard [52] and Abu Samah and Heard [57]. 
Finally, results are visualized and relative COX-2 levels determined 
following densitometric scanning, which can be used on a purely qual-
itative basis. For semi quantitative data (i.e., COX-2 levels relative to 
a control), the Western blot band intensities are normalized against a 
ubiquitous protein, typically β-actin [58], which is run simultaneously 
and arbitrarily set to 100%. Each experiment should be performed in 
≥ triplicate for each sample and the result expressed as the mean ± SD.
Analysis of inflammatory prostaglandin E2 levels
Skin extracts such as the lysates prepared in Section 8.3 may also 
be analyzed for COX-2 product prostaglandin, although analyzable 
samples may also be obtained more simply using a probe homogenizer. 
Enzyme immunosorbent assay (EIA) kits are commercially available, 
e.g., Cayman Chemical which involves and incubation: 18 h, devel-
opment in 60–90 min and colorimetric determination at 405–420 nm; 
and has a range of 7.8–1000 pg/ml and sensitivity of 15 pg/ml. GCMS 
and LCMSMS are also used for such analyses.
Immunohistochemical analysis of COX-2 in ex vivo 
skin
To supplement the WB data the relative levels of COX-2 expression 
in skin may be visualized prior to lysing, allowing visual qualitative 
comparison of anti-inflammatory effects relative to an untreated control. 
IHC is already embedded as a major diagnostic tool in pathology for 
many markers [59], including COX-2 [60]. Unlike WB, the analysis 
of COX-2 is performed in situ rather than following liberation from 
the tissue, e.g., in punch biopsies [61]. The general methodology is 
explained in detail in the literature. However, it is worth stressing that 
effective preparation of the skin sample is critical to maintain cell mor-
phology, tissue architecture, antigenicity and the level and location of 
target epitopes. Consequently, exacting tissue collection, fixation and 
sectioning protocols are essential.
PUBLISHED DATA USING THIS APPROACH
Background levels
Viable, but otherwise untreated ex vivo skin universally displays 
elevated levels of COX-2 and PGE-2, as evidenced in later sections 
by WB and intense IHC staining and is a response to combination of 
shutting down, ear excision and the preparation processes prior to use. 
The control tissue thus provides background levels of conveniently 
upregulated COX-2 and PGE-2 against which to compare test sub-
stances and formulations, via either pro-inflammatory action (where 
the levels increase post treatment) or, usually, anti-inflammatory (where 
the levels decrease post treatment). Background levels are determined 
in each experiment for internal consistency, and modulations due to 
treatment determined statistically, generally using one-way analysis 
of variance (ANOVA) followed by appropriate post-tests, using InStat 
for Macintosh, version 3.0 (GraphPad Software Inc, San Diego, CA).
Positive controls
Although the topical delivery and activity of anti-inflammatory 
activity is important in its own right, their inclusion in our work to 
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date has largely been as validators, i.e., to serve as positive controls, as 
successful delivery to the viable epidermis should be reflected in lower 
levels of epidermal COX-2 relative to untreated skin. In the following 
examples, the level of activity was variable and this is due to numerous 
factors including: dosage form, concentration of drug, amount dosed 
and excipient effects - indeed optimization of such factors is pivotal in 
the development of new topical formulations.
Ibuprofen is a commonly used non-steroidal anti-inflammatory 
drug (NSAID) of the profen-type and is available as topically applied 
hydrogels (e.g., 5% Ibuprofen pain relief gel, 10% Ibugel Forte, Dermal 
Laboratories). More recently a cutaneous lotion has become available 
to treat minor sunburn (Soleve sunburn relief, Diomed Developments 
Limited), which contains 1% ibuprofen and claims to be clinically 
proven for relieving the pain and soreness of mild to moderate sunburn. 
Using the current model, solutions of ibuprofen have been used as 
positive control to determine the relative anti- and pro-inflammatory 
effects of H. procumbens (Devil’s claw) where WB analysis revealed 
that, following the dosing of 500 µM ibuprofen in PBS onto the skin 
for 6 h, COX-2 was reduced by ~50% [52,62].
Ketoprofen is another non-steroidal anti-inflammatory of the pro-
fen-type and is available as hydrogel (e.g., 2.5% Oruvail, Sanofi; 
ketoprofen 2.5% w/w gel, Pinewood Healthcare). Using the current 
model, 2.5% aqueous ketoprofen solution was used as a control for the 
anti-inflammatory effects of a formulation containing both ketoprofen 
and Ω-3 fatty acids in a two-pronged anti-inflammatory system. IHC 
analysis revealed that whereas ketoprofen exerted no effect upon LOX 
expression, a significant decrease on COX-2 expression was observed 
[63]. Naproxen, also a non-steroidal anti-inflammatory drug of the 
profen-type, was the focus of a novel topical drug delivery system 
involving activated nanogels, where is also served as a control when 
dosed as a simple solution. Compared to untreated ex vivo skin, Western 
blot analysis showed the naproxen solution elicited anti-inflammatory 
activity by the reduction of COX-2 to 88.6% after 6 h and 84% after 
10 h post-application [64].
Betamethasone and betamethasone dipropionate, like most gluco-
corticoids, possess potent anti-inflammatory activities. However, the 
mechanism of action differs to profen-type NSAIDs and involves the 
synthesis of lipocortin-1 (annexin-1) which suppresses phospholipase 
A2, thereby blocking eicosanoid production. In the work of Zulfakar 
et al., another 2-pronged anti-inflammatory system was investigated 
based upon a combination of betamethasone dipropionate and omega-3 
fatty acids [50]. A dose of 0.5 g of an ointment containing 0.1% w/w 
betamethasone dipropionate (plus 3% salicylic acid intended to model 
Diprosalic ointment) was applied to ex vivo porcine skin. IHC analysis 
revealed a reduction in the intensity of COX-2 staining after 6 h and 
analysis by enzyme-linked immunosorbent assay (ELISA) analysis 
further revealed the level of PGE-2 had decreased by 50%.
Fish oil and Ω-3 polyunsaturated fatty acids
Fish oil has been extensively researched due to the purported health 
benefits conferred by its constituent major Ω-3 fatty acids: eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA). These are associated 
with anti-inflammatory activity, resulting from the formation of less 
potent eicosanoids compared to those derived from Ω-6 fatty acids, 
mainly AA [65,66]. Typical levels in fish oil are EPA (33%) and DHA 
(22%) and with sufficient bioavailability they can be incorporated into 
cell membranes from where it subsequently competes with AA in the 
inflammation cascade [67]. In addition to its anti-inflammatory activity, 
Ω-3 fatty acids can act as a skin permeation enhancer in formulations 
containing fish oil and NSAIDs, where the amount of NSAID and EPA 
from the fish oil delivered to the skin was increased compared to fish 
oil or NSAIDs alone [68,69].
In our laboratory, fish oil has generally been co-administered with 
an anti-inflammatory drug such as ketoprofen or betamethasone dipro-
pionate with the aim of developing a two-pronged therapeutic to treat 
acute inflammation. Ketoprofen blocks synthesis of prostaglandins by 
COX-2, whilst high bioavailability of fish oil directs the remaining 
prostaglandin to more benign forms incorporating EPA and DHA. 
Similarly, betamethasone dipropionate reduces eicosanoid production 
by blocking phospholipase A2 production, and co-administered with 
fish oil again directs the remaining prostaglandin to more benign forms 
incorporating EPA and DHA.
Using the general approach outlined above the effect of topically 
applied fish oil and ketoprofen on cyclooxygenase (COX-2) and lip-
oxygenase (LOX) were determined within freshly excised porcine ear 
skin [63]. IHC data revealed that the fish oil formulation qualitatively 
inhibited the expression of both COX-2 and LOX enzymes. A formu-
lation containing both fish oil and ketoprofen proved to be the most 
effective at inhibiting the expression of both COX-2 and LOX, further 
demonstrating that permeation of the fish oil enhanced the permeation 
of ketoprofen; enhancement behavior was attributed at least in part to 
π-π interactions [70].
The ex vivo porcine ear model was used to probe the influence of 
co-formulated fish oil on the topical delivery and anti-inflammatory 
properties of betamethasone dipropionate from ointment formulations 
[50]. The skin was probed by IHC for COX-2 and the tissue was also 
assayed for PGE-2 using a commercially available ELISA kit (Cayman 
Chemical, Ann Arbor, MI). Expression of COX-2 is known to decrease 
in response to the presence of glucocorticoids [7]. The data showed that 
whereas betamethasone and salicylic acid reduced COX-2 expression 
within the epidermis, greater reduction was observed when fish oil was 
included in the ointment, as indicated by reduced COX-2 expression. 
Modulation of PGE-2 production also supported the anti-inflammatory 
properties of fish oil, reducing PGE-2 levels that reflected the reduction 
by betamethasone dipropionate. However, combining fish oil with beta-
methasone dipropionate did not provide the anticipated synergistic effect 
i.e., no further COX-2 reduction was observed. Addition of fish oil also 
enhanced the anti-inflammatory activity of betamethasone dipropionate, 
attributed to increased amounts of the drug present in the skin and/or 
the intrinsic anti-inflammatory activity of fish oil (Fig. 2). Fish oil is a 
complex mixture of fatty acids as triacylglycerols and ethyl esters, in 
addition to other components, such as antioxidants. Some compounds 
have pro-inflammatory activity, such as AA [66]. Therefore, rather than 
propose that fish oil has anti-inflammatory activity, it is more accurate to 
say the anti-inflammatory compounds such as EPA and DHA counteract 
the presence of pro-inflammatory factors leading the downregulation 
of COX-2 as observed in the current model.
Devil’s claw (Harpagophytum procumbens) extract
Devil’s claw is the common name for the prepared tuber of the 
southern African plant, H. procumbens (L.) and for centuries it has been 
used as a folklore treatment for a variety of inflammatory disorders 
[71]. As a natural product, its extracts contain a wide array of chemical 
compounds, although its major phytochemical components, harpagoside, 
J Biol Methods  | 2020 | Vol. 7(4) | e138 7
POL Scientific
Review
harpagide, 8-coumaroylharpagide and verbascoside were believed to 
be responsible for its anti-inflammatory effects.
Using the methods described above, an ethanol-soluble extract of 
H. procumbens tubers and two of the pure compounds tested showed 
reductions in COX-2 in WB and IHC analysis, with harpagoside and 
8-coumaroylharpagide exhibiting greater reductions in COX-2 expression 
than verbascoside [62]. Dosing with ibuprofen led to a 40% decrease 
in COX-2 (Fig. 3).
It was surprising to discover that the compound harpagide in fact 
caused a significant increase in the levels of COX-2 expression above 
control levels after 6 h of topical application. The data therefore suggest 
that the efficacy of H. procumbens is dependent upon the ratios of the 
phytochemicals present, which is inconsistent with some current official 
monograph specifications based solely on harpagoside content. With 
this in mind, the relative efficacies of six commercial formulations of 
H. procumbens were evaluated [72]. Based upon the recommended 
dosages on the product label, the total daily amounts were determined 
and used to establish anti-/pro-inflammatory (A/P) factors; again the 
formulations were compared using ex vivo porcine skin for their activ-
ities towards COX-2 by WB. The results showed great variability in 
the phytochemical composition of the six formulations examined and 
this inconsistency correlated with relative COX-2 expression (Fig. 4). 
The conclusion was that although the data supported the beneficial 
anti-inflammatory effects from the use of some of the brands tested, 
others would appear potentially to exacerbate inflammation.
Figure 2. The effects of topically applied betamethasone diproprionate and fish oil on porcine skin ex vivo. A. Immunohistochemical staining for 
the presence of COX-2 in ex vivo skin following 4 treatments at different time points at 40× magnification. Key: a1. control, a2. betamethasone dipropi-
onate, a3. fish oil, a4. betamethasone dipropionate + fish oil, after 0 h; b1. untreated, b2. betamethasone dipropionate, b3. fish oil, b4. betamethasone 
dipropionate + fish oil after 6 h (n = 3 ± SEM). Note the very low staining when fish oil was combined with BD in a single formulation. B. Levels of PGE-2 
in ex vivo skin. Key: 1. untreated control, 2. betamethasone dipropionate, 3. fish oil, and 4. betamethasone dipropionate + fish oil for 6 h (n = 3 ± SEM). 
Treatments 2–4 all significantly reduced PGE-2 in ex vivo skin relative to untreated skin P < 0.05 (one way ANOVA followed by Dunnett’s post hoc tests). 
Note: topically applied fish oil gave a similar result to topically applied steroid betamethasone dipropionate, although a combination provided no further 
reduction.
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Figure 3. Effects of the components of Devils claw (H. procumbens) ethanolic extract on the expression of COX-2 in ex vivo porcine skin (n = 3 
± SD) where β-actin was used as the housekeeping protein. Key: 1. untreated control, 2. H. procumbens ethanolic extract, 3. admixture (harpagoside, 
8-coumaroylharpagide, verbascoside), 4. admixture (harpagoside, harpagide, 8-coumaroylharpagide, verbascoside), 5. harpagoside (P < 0.05), 6. harp-
agide (P < 0.05), 7. 8-coumaroylharpagide (P < 0.05), 8. verbascoside (P < 0.05) and 9. ibuprofen (P < 0.05) (one way ANOVA followed by Dunnett’s post 
hoc comparisons). Note: anti-inflammatory activity of harpagoside, 8-coumaroylharpagide and verbascoside, but pro-inflammatory activity of harpagide.
Figure 4. Effects of the topical application of commercial Devil’s claw formulations 3–8 and positive control 2 on the expression of COX-2 in 
ex vivo porcine skin, where 1 is untreated control; β-actin was used as the housekeeping protein. A. Bar chart (n = 3 ± SD), where β-actin was 
used as the housekeeping protein. B. Western blots for COX-2 expression. One way ANOVA followed by Dunnett’s post hoc comparisons revealed only 
product 4 to be anti-inflammatory (P < 0.05), whereas products 6 and 8 were pro-inflammatory (P < 0.05). The identity of 3–8 can be found in Abde-
louahab and Heard [72]. Note: the wide variations in pro- and anti-inflammatory activities of the six commercial Devil’s Claw (H. procumbens) products.
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Pomegranate rind extract and punicalagin
Pomegranates are obtained from the fruit of the Punica granatum 
(L.) tree, and pomegranate rind extract (PRE) contains a high level of 
polyphenolics, in particular, tannins such as punicalagin. When co-ad-
ministered with Zn (II) ions, pomegranate rind extract (PRE) has been 
found to be a potent microbicidal system [73], with potential as a new 
topical treatment for Herpes simplex virus (HSV) infections and inflamed 
perioral lesions. The anti-inflammatory activity of PRE total pomegranate 
tannins (TPT) and zinc (II) were studied from pH 4.5 phthalate buffer 
solutions using the ex vivo porcine skin model by assessing their effect 
on the expression of endogenous COX-2 by WB and IHC [19]. Results 
revealed that the application of PRE and PRE + ZnSO4 both led to the 
statistically significant (P > 0.01) reduction of COX-2 expression by 
66.5 ± 3.6% and 64.5 ± 5.1%, respectively (Fig. 5A).
Figure 5. The effects of topically applied pomegranate rind extract and zinc sulfate on porcine skin, ex vivo. A. Bar chart showing COX-2 expres-
sion by Western blotting after full thickness porcine skin was treated with topical ZnSO4 (1 M), pomegranate rind extract (PRE) (1 mg/ml), PRE (1 mg/
ml) + ZnSO4 (1 M) and phthalate buffer as a control for 6 h, protein was extracted and 30 µg was loaded and separated via SDS-PAGE. The histogram 
represents COX-2 (72 kDa) levels normalized against β-actin (42 kDa). Note: significant anti-inflammatory activities of PRE, PRE + ZnSO4 and TPT 
(one way ANOVA followed by Dunnett’s post hoc analysis), indifferent effect of ZnSO4 and TFF. B. Western blots for COX-2 expression. C. Reverse tape 
stripping of porcine epidermis: punicalagin recovered after 24 h by reverse tape stripping three times epidermal membranes (where 1 is the basal layer) 
dosed with two formulations, F1 (left) and F2 (right) (mean ± SD, n = 4). Note: significantly higher levels of anti-inflammatory punicalagin in basal layer 
(one way ANOVA followed by Mann-Whitney U test).
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The reduction of COX-2 by PRE was similar to that previously 
reported where COX-2 reduction of 79% was observed in colon cancer 
cells [74]. Using one-way ANOVA analysis, the application of ZnSO4 
demonstrated no statistically significant effect on the level of COX-2 
expression (P > 0.05), in line with data previously shown [75]. COX-2 
was also downregulated following the application of an equal concentra-
tion of TPT but this level (40.5%) was significantly higher (reduced by 
only 26%) than the result obtained from PRE in the presence or absence 
of ZnSO4. A tannin-free PRE (i.e., PRE after tannins removed) failed 
to show any modulation of COX-2. The WB data were supplemented 
by IHC that followed the same trend. Therefore, reduction in COX-2 
expression was determined to be greatest when PRE remained as a whole 
extract, with TPT (even with its high punicalagin content) exhibiting 
anti-inflammatory activity to a lesser extent. Olajide et al. reported the 
pre-treatment of rat primary microglia with punicalagin (5–40 μM) 
prior to LPS (10 ng/ml) stimulation which produced a significant (P 
< 0.05) inhibition of TNF-α, IL-6 and PGE-2 production; protein and 
mRNA expressions of COX-2 and microsomal prostaglandin E synthase 
1 were also reduced by punicalagin pretreatment [76]. PRE and Zn (II) 
was subsequently formulated as hydrogels and then used to determine 
permeation across epithelial membranes prone to HSV infection [77]. 
When PRE/Zn (II) gels at two concentrations were applied to porcine 
epidermis, the gel with the higher loading showed higher permeation 
than the one with the lower loading. However, when the amount of 
punicalagin in the basal layer was determined by reverse tape stripping 
(whereby the basal layer is stripped first), the same amounts were 
found to have been delivered from each gel. COX-2 reduction was 
found to be 33% relative to the untreated control. This shows firstly, 
that the tissue was saturated with punicalagin using both formulations 
(Fig. 5B) and secondly, that the level of punicalagin delivered to the 
lower layers was sufficient to elicit an anti-inflammatory response A 
further novel approach was taken in that study whereby the receptor 
phase was collected at the end of the experiment and then used to dose 
ex vivo porcine skin in further diffusion cells. COX-2 expression was 
reduced by 64% relative to control after 6 h, confirming the delivery 
of anti-inflammatory levels across skin.
It is notable that the above data were achieved with intact stratum 
corneum, confirming skin penetration of punicalagin and Zn(II); how-
ever, the molecular weights of punicalagin and the Zn(II) ion are 1084 
and 65 respectively, and are both differ markedly from the generally 
accepted optimum of ~400 [48,19]. Given the clear anti-inflammatory 
effects observed, appendageal delivery via shunt routes [78] may have 
been of significance here.
Nanoparticles
Nanotechnology remains a major growth area of research for new 
therapeutic systems including topical delivery. Stimulus-responsive 
nanogels, i.e., those that release drug depending on such parameters as 
temperature and pH, have potential as carriers for drugs targeting the 
skin. The current ex vivo porcine skin model has been used to examine 
potential anti- and pro-inflammatory effects associated with the topical 
application of these materials.
As such products are directly in contact with skin, and evidence 
has been published to show they can permeate across skin [79], it was 
important to determine the potential to induce irritation or inflammation. 
The ex vivo porcine ear model has been used to estimate the biocom-
patibility of polyN-isopropylacrylamide (polyNIPAM), poly(NIPAM 
copolymerized butyl acrylate) [poly(NIPAM-co-BA)], and poly(NIPAM 
copolymerized with 5% w/v acrylic acid) [poly(NIPAM-co-AAc)(5%)] 
nanogels [57]. WB of skin lysates for COX-2 expression demonstrated 
that the materials had penetrated the skin and interacted with keratino-
cytes of the viable epidermis. The poly(NIPAM-co-BA) nanogel was 
found to elicit a pro-inflammatory response when applied topically, 
as reflected by 67% higher COX-2 expression relative to the control 
treatment (Fig. 6A). The data obtained for the poly(NIPAM-co-AAc)
(5%) nanogel, on the other hand, indicated no significant modulation in 
the expression of COX-2, suggesting the particles are compatible with 
skin (Fig. 6B). This was even the case in the presence of co-adminis-
tered aqueous citric acid solution. Overall the data support the use of 
the multi-responsive poly(NIPAM-co-AAc)(5%) nanogel for triggered 
topical drug delivery applications. However, nanoparticles are often 
intended to be the vector for delivering a loaded drug to the target site. 
If the loaded drug is an anti-inflammatory it can compensate for any 
pro-inflammatory effects of the nanogel itself, such that the net effect 
in one of anti-inflammatory activity.
Methotrexate is a potent folate analogue that reduces the activity of 
the body’s immune system, which may be overactive in some conditions 
such as rheumatoid arthritis, psoriatic arthritis and vasculitis. Metho-
trexate is approved by the FDA to treat psoriasis, and it continues to 
be a first-line treatment for psoriatic arthritis where is it exerts indirect 
inhibition of COX-2 synthesis [80]. The ex vivo porcine skin model 
was used to demonstrate the improved dermal delivery of methotrexate 
utilizing activated nanogels based on co-polymerized polyNIPAM and 
butylacrylate [81]. In so doing, a novel mechanism was established 
whereby the change in temperature experienced by the nanogel as it 
penetrated skin induced de-swelling and expulsion of methotrexate in 
situ. Finite doses were applied to full-thickness porcine ear skin ex vivo, 
which was then treated with radioimmunoprecipitation buffer and probed 
for levels of PGE-2 using a commercial enzyme immunoassay kit. The 
added sodium carbonate led to further solubilization and MTX release, 
hence increasing the concentration gradient, flux and reducing PGE-2 
production. The methotrexate-loaded nanogel, which demonstrated 
de-swelling by 7% over the range 25–37°C, provided a methotrexate 
flux of 1.4 ± 0.3 ng/cm2/h; this increased to 3.1 ± 0.22 ng/cm2/h upon 
the addition of saturated aqueous. PGE-2 levels for water (control) 
and sodium carbonate) were similar, but reduced by 33% when the 
methotrexate-loaded nanogel was applied, and by 57% when this was 
followed by the application of sodium carbonate (P < 0.01, ANOVA).
A similar responsive system was used to determine the modulation 
of skin COX-2 levels with polyNIPAM nanogels loaded with naproxen 
[64]. Nanogels were prepared under standard and acidic conditions using 
citric acid whereby the nanoparticles were in an expanded state allowing 
maximal expansion, prior to collapse and drug expulsion by addition 
of base. Following massaging into skin, the skin was probed (with and 
without base activation by sodium carbonate (or triethylamine) for depth 
penetration and transdermal delivery of drug, and anti-inflammatory 
activity in the relative levels of COX-2 expression (Fig. 7A). When 
activated by sodium carbonate, there was a particle size reduction of 
19%. Tape stripping revealed significantly greater delivery of naproxen 
into the epidermis for the activated nanogel and the steady state flux 
was enhanced by a factor of 2.8. WB showed reduced COX-2 with 
base-activated nanogel was 50% lower than unactivated nanogel, and 
this trend was confirmed semi-quantitatively by immunostaining (Fig. 
7B). Importantly, this work included an in vivo evaluation using the 
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rat paw oedema test which further confirmed the increased activity of 
the activated nanogel in the reduction of rat paw swelling, providing 
ex vivo–in vivo correlation (Fig. 8).
Figure 6. The effects of topically applied nanogels on COX-2 expression in porcine skin, ex vivo. A. Western blotting analysis of COX-2 expres-
sion in full-thickness ex vivo porcine skin following topical treatment for 9 h (n = 3 ± SD). β-actin was used as the housekeeping protein. Key: 1. control 
(de-ionized water), 2. NIPAM monomer (1% w/v), 3. polyNIPAM, 4. poly(NIPAM-co-BA), 5. MTX (positive control). Note: pro-inflammatory response from 
topically applied poly(NIPAM-co-BA) nanogel (4), as reflected by 67% higher COX-2 expression relative to the control treatment (P < 0.05, one-way ANOVA 
with Tukey’s post hoc test). B. Western blots for COX-2 for (A). C. Western blotting analysis of COX-2 expression in full-thickness ex vivo porcine skin 
following topical treatment for 9 h (n = 3 ± SD). β-actin was used as the housekeeping protein. Key: a. control (de-ionized water), b. NIPAM monomer 
(1% w/v), c. AAc monomer (0.05% v/v), d. aqueous solution of CA (5% w/v), e. polyNIPAM, f. poly(NIPAM-co-AAc)(5%), g. poly(NIPAM-co-AAc)(5%) 
followed by CA solution, h. positive control (methotrexate). Note: generally better skin compatibility of blank nanoparticles based on poly(NIPAM-co-AAc)
(5%) (P < 0.05, one-way ANOVA with Tukey’s post hoc test). D. Western blots for COX-2 for (C).
DISCUSSION
Generally, live animals are the mainstay of anti-inflammatory ac-
tivity determinations, prior to testing in humans. Although relatively 
straightforward, such techniques incur significant costs due to husbandry 
and licensing. Furthermore, TPA and rat paw oedema tests undeniably 
cause pain and discomfort to the subject animals, which by convention 
would be sacrificed at the end of the procedures and are therefore are 
not aligned with the current drive for “3 Rs”—reduction, refinement 
and replacement [21]. The principle of the 3 Rs has become embedded 
in national and international legislation regulating the use of animals 
in scientific procedures. It may appear counter-intuitive that the use of 
excised porcine skin also does not fit with 3 Rs philosophy. However, 
porcine ears are generally unwanted byproducts of the food industry, 
in the UK at least, and involve animals that have already been slaugh-
tered. Wider adoption of the general approach outlined in this article 
has potential significance in the Replacement and Reduction of in vivo 
experiments using live animals, for example in the development of 
further products intended for topical application.
Importantly for this protocol, the death of the pig in addition to 
the crude processing of the ear tissue renders the skin in a state of 
inflammation prior to experimentation. This is something observed in 
all our studies, and it provides a convenient platform against which 
to determine anti-inflammatory activity, bearing in mind that COX-2 
and eicosanoids are constitutive and have very short half-lives. No 
prior treatment is required to induce inflammation, e.g., with TNF-α, 
to stimulate eicosanoid production, which in itself could subsequently 
modulate the delivery and efficacy of the test substance. The anti-in-
flammatory effects observed in the cases described above arise from 
modulation key events in the AA pathway [82]. Conversely, the applica-
tion of pro-inflammatory compounds induces such events, for example 
as observed with harpagide [62]. As a constitutive enzyme, COX-2 is 
absent or in very low concentration in most normal tissues; however, 
it is induced at sites of inflammation by cytokines, growth factors and 
tumor promoters. Downregulation of eicosanoid production can be taken 
to mean that the permeant has docked within the active site of COX-2 
and therefore inhibited the biosynthesis of further PGE-2, and therefore 
via negative feedback has resulted in less COX-2 being expressed, as 
COX-2 is strongly induced by pro-inflammatory challenges. However, 
the active site of COX-2 is well documented and blockade of the COX-
2 active site is the MOA for NSAIDs such as the profens which have 
been designed to fit into this pocket. However, the literature contains 
reports of compounds that have a modulating effect on COX-2 inhibi-
tors, although their chemistries cannot be rationalized in terms of active 
site pocket fitting. These include flavonoids [83,84] and pomegranate 
rind extract and the polyphenolic punicalagin [73]. These have potent 
antioxidant properties and can deactivate the free radicals generated in 
first stage of AA conversion by COX-2. As the function of COX-2 is to 
catalyze the production of eicosanoids, it is intuitive that a reduction in 
COX-2 should go hand in hand with reduction in PGE-2. However, in 
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reality the situation is not so clear. Additionally, the bioavailability of 
Ω-3 fatty acids (EPA, DHA) should be manifested in a reduction in the 
level of PGE-2. This was observed by Zulfakar et al., where the reduction 
of PGE-2 was rationalized in that the topical application of fish oil 
resulted in competition between the Ω-3 fatty acids and AA, producing 
a different series of prostaglandins which are less potent inflammatory 
mediators than its AA-derived counterparts [50]. The presence of more 
benign prostaglandins would feedback and cause downregulation of 
COX-2, which could further explain the reduction in PGE-2 levels.
Figure 7. Effects of topically applied naproxen-loaded thermorespnsive nanogels on porcine skin, ex vivo. A. Representative Western blots for 
COX-2 expression following the dosing of porcine skin with naproxen-loaded PNIPAM nanogels after 6 and 10 h, relative to water control. β-actin was 
used as the housekeeping protein. The upper blots show COX-2 for each treatment where the intensity of the bands and is directly proportional to protein 
level. The lower blots show the β-actin control (n = 3 ± SD). Key: 1. control (untreated), 2. NNCA + TEA (naproxen nanogel + citric acid + triethylamine) 
at 6 h, 3. NNCA + TEA (naproxen nanogel + citric acid + triethylamine) at 10 h, 4. Naproxen solution at 10 h, 5. NNCA (naproxen nanogel + citric acid + 
sodium carbonate) at 6 h, 6. NNCA (naproxen nanogel + citric acid + sodium carbonate) at 10 h, 7. NNCA + SC (naproxen nanogel + sodium carbonate) 
at 6 h, 8. NNCA + SC (naproxen nanogel + sodium carbonate) at 10 h, 9. naproxen solution at 6 h. Note: significant anti-inflammatory active of naprox-
en-loaded nanogels, in particular from those involving the addition of sodium carbonate (one way ANOVA followed by Dunnett’s post hoc analysis). 
B. Western blots for COX-2 in ex vivo porcine skin. C. Representative immunostaining images for COX-2 in ex vivo porcine skin dosed with PNIPAM 
nanogels. Ex vivo porcine skin treated with: BN (blank nanogel) after 6 h (top left), BN (blank nanogel) after 10 h (bottom left), NNCA (naproxen nanogel 
+ citric acid) after 6 h (top center), NNCA (naproxen nanogel with citric acid) after 10 h (bottom center), NNCA + SC (naproxen nanogel with citric acid, 
then sodium carbonate) after 6 h (top right), NNCA + SC (naproxen nanogel with citric acid, then sodium carbonate) after 10 h (bottom right). Note: high 
staining (high COX-2) in the blanks, lower staining (lower COX-2) when naproxen nanogel applied, much lower staining (much lower COX-2) following 
the application of sodium carbonate causing the greater release of naproxen in situ.
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Figure 8. Time course of carrageenan-induced oedema in the in vivo rat paw test following administration of PNIPAM nanogels. Results, ex-
pressed as % swelling determined at different times after injection of carrageenan in the left hind foot pad. Key: Green: naproxen solution control, Blue: 
blank nanogel control, Red: NNCA (naproxen nanogel with citric acid), Black: NNCA + SC (mean ± SD, n = 3). Note: lowest swelling when dosed with 
NNCA + SC (naproxen nanogel + citric acid, activated by sodium carbonate).
Furthermore, although it had been generally accepted that the phar-
macological action of NSAIDs is mediated by inhibiting the activity of 
COX [85], some drugs can have the effect, at least in part, of suppressing 
COX-2 gene transcription. First reported by Xu et al., the pharmaco-
logical action of salicylate could not be explained by its inhibition of 
cyclooxygenase activity, rather that salicylate exerts its anti-inflammatory 
action in part by suppressing COX-2 induction, thereby reducing the 
synthesis of pro-inflammatory prostaglandins [86]. Modulation of any 
of these processes will result in lower PGE-2 production and result in 
the downregulation of COX-2 via negative feedback. However, as noted 
in some of the above cases, application of some compounds to skin can 
exacerbate inflammation, as shown by the eliciting of the upregulation 
of COX-2 expression. This is evidenced by increased levels of COX-2 
compared to control e.g., harpagide [62].
A further key attribute of the current protocol is that the very fact the 
penetrant molecules have achieved this modulation is direct evidence 
that it has successfully penetrated the skin, in particular the barrier func-
tion of the fully differentiated stratum corneum, in sufficient amounts 
to elicit such a response. In comparison with reconstructed epidermis 
models, in which the stratum corneum typically lacks normal struc-
ture, e.g., in terms of lipoidal domains and presence of appendages, 
the current model is superior in better mimicking an in vivo scenario. 
Furthermore, such models lack appendages, and sweat pores are found 
over the entire body with a density of 400 glands per cm2 and have 
the purpose of exuding sweat, an aqueous electrolyte solution. Given 
the clear anti-inflammatory effects with PRE such channels appear to 
provide a short-cut by allowing the permeants to bypass the barrier 
function of the stratum corneum which is primarily lipoidal in nature. 
This is sometimes referred to as a “shunt route” [78] and its effect can 
only be truly accounted for using natural skin.
Limitations of this protocol primarily relate to the fact that despite 
the use of buffers that support viability, the tissue tends to undergo 
necrosis between 24 and 48 h. The limited lifespan in ex vivo systems 
is a recognized limitation, and the model is not appropriate for study-
ing modulation of cutaneous inflammation over prolonged timescales 
[87]. The lack of connectivity with other tissues is a potential issue 
with all ex vivo systems, for example the effect of changes in COX-2 
and PGE-2 levels on regional blood flow (erythema) and pain cannot 
be determined. Also, the tissue is not available through a supplier, 
and has to be obtained directly from a cooperative abattoir, although 
laboratory-bred animals could be used equally effectively. A summary 
of the advantages and disadvantages of this and competing techniques 
is shown in Table 1.
This protocol has focused upon the modulation of the AA/COX-2 
inflammation pathway as a consequence of the topical application of 
xenobiotic compounds. The use of the technique to study phototoxicity 
and sunscreen efficacy in terms of modulation of the AA pathway is 
currently in progress. However, there are numerous other signaling 
pathways within the skin that could potentially be probed based up the 
general methodology described herein, although whereas COX-2 was 
universally modulated in the examples given, attempts to determined 
modulation of 5-LOX in this model were less predictable; the reason for 
this remains unclear. The current model is by its very nature a composite 
of xenobiotic transport and biological activity. Indeed, biological activity 
can only be observed if sufficient compound has penetrated the skin 
and diffused across the stratum corneum to the dividing keratinocytes 
of the viable epidermis.
Finally, it is recognized that this review relates almost entirely to the 
work carried out in the author’s laboratory. It is hoped the approaches 
described can be adopted more widely in the area of topical drug de-
livery system development.
CONCLUSION
In this article, a reproducible protocol has been described for de-
termining the modulatory effects of topically applied xenobiotics on 
the arachidonic acid inflammation pathway within ex vivo skin. The 




1. Freshly excised porcine ears are generally accessible, inexpensive 
and free of ethical restrictions.
2. Modulation of short-lived COX-2 is a useful marker for skin 
inflammation, as it is directly linked to PGE-2 levels.
3. Determination readily achieved by regular molecular biology 
techniques: semi quantitative WB and/or qualitative IHC.
4. Able to provide direct evidence of xenobiotic (pro- or anti-in-
flammatory) penetration across the stratum corneum to the viable 
epidermis, including shunt routes, unlike cell culture and reconstructed 
epidermis models.
5. Based on ex abattoir material, the method is conducive to broad 
3 Rs philosophy, and has potential for the significant “replacement” of 
live animal experimentation.
Table 1. Summary of the advantages and disadvantages of non-clinical techniques available to study cutaneus inflammation.
Technique Advantages Disadvantages
Animal paw, in vivo • Availability
• Established technique
• Modulations are indirectly related to inflammation
• Utilization of and stress to live animals
Cell culture • Availability of immortalized cell lines • Sensitive methodology
• No connectivity to other tissues
• Results have no relationship to skin penetration or 
permeation
Human reconstructed tissue • Quality controlled material





• Lack of appendages and fully differentiated stratum 
corneum
• No connectivity to other tissues
Ex vivo porcine • Xenobiotic penetration and permeation known to be 
similar to human skin
• Native, fully differentiated barrier function
• Pharmacological effect proves drug penetration
• Absence of effect proves insufficient drug penetrated
• 3 Rs compliant
• Inexpensive
• Must be used rapidly post slaughter
• Not suitable for long term study
• No connectivity to other tissues
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